Verdiva Bio to present data on once-weekly potential of its investigational oral obesity candidates at 61st EASD Annual Meeting

- ***Proof of concept for potential once-weekly oral administration of VRB-101, Verdiva Bio's, cAMP-biased oral GLP-1 analog in phase 1***
- ***Preclinical data on VRB-103, Verdiva Bio's potential once-weekly, oral amylin analog - supports continued development, both as monotherapy and in single tablet co-formulation with VRB-101***

LONDON AND SAN FRANCISCO – 1st September, 2025 – Verdiva Bio Limited ("Verdiva" or "the Company") a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present data on the once-weekly potential of Verdiva's investigational oral GLP-1 and amylin analog peptide candidates at the European Association for the Study of Diabetes Congress on 15-19 September 2025.

Jane Hughes, President, R&D *at Verdiva said, "Our data demonstrates the once-weekly dosing potential of our portfolio of investigational oral candidates, both as monotherapies and as combinations. In particular, this data highlights the potential of our oral amylin analog and our once-weekly oral GLP-1 in a fixed dose combination"*

She added: "We also have the ability to explore the optimal GLP-1/amylin ratio in the clinic to find the best efficacy and tolerability balance for patients. The flexibility of our approach reflects our commitment to developing convenient, patient-friendly and commercially scalable therapeutic options for obesity, cardiometabolic disorders and related complications."

VRB-101: An investigational potentially once-weekly oral GLP-1 analog

This presentation highlights the clinical pharmacokinetic data for VRB-101, an investigational, once-weekly, cAMP-biased oral GLP-1 analog formulated with Verdiva's clinically validated, proprietary oral delivery technology T2026.

Phase 1 results demonstrated that oral VRB-101 achieved drug levels comparable to, or exceeding, those of currently available once-weekly injectable GLP-1 analog therapies. These findings support continued investigation of VRB-101 as a potential once-weekly,

scalable oral therapeutic option for both weight reduction and long-term weight maintenance in people living with obesity or overweight with weight-related comorbidities.

Oral Presentation #1
Title: *VRB-101 is a potent oral GLP-1 tablet with once-weekly dosing potential*
Presenter: Mohamed Eid, MD, Chief Medical Officer, Verdiva Bio

Date/Time: Wednesday Sep 17, 2025, 3:00pm CEST
Location: Milan Hall

VRB-103: An investigational potentially once-weekly oral amylin analog, under development as a monotherapy and in combination with VRB-101

This presentation conveys novel preclinical data on VRB-103, an investigational potentially once-weekly oral amylin analog, tested alone and in combination with VRB-101.

The presentation highlights the co-formulation of these peptides in a single tablet with Verdiva's clinically validated, proprietary oral delivery technology, T2026. When co-formulated, VRB-101 and VRB-103 maintained comparable plasma exposure. These data support continued development of VRB-103 as both a monotherapy and in combination with VRB-101. Verdiva's aim is to balance efficacy and tolerability of these compounds through ratio optimization in clinic.

Oral Presentation #2
Title: *Efficacy of a novel oral amylin analog and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures*
Presenter: Jane Hughes, President, R&D, Verdiva Bio

Date/Time: Friday Sep 19, 2025, 10:30am CEST
Location: Paris Hall

-Ends-

Contact Information

Verdiva Bio info@verdivabio.com
Charlotte Davison, Chief of Staff

Vigo Consulting (Media) +44 20 7390 0230
Melanie Toyne-Sewell VerdivaBio@VigoConsulting.com
Rozi Morris

About Verdiva Bio

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva's most advanced product candidate is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential efficacy in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing potential. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.

For more information, please visit www.verdivabio.com.